<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03165253</url>
  </required_header>
  <id_info>
    <org_study_id>2011-10-08/03</org_study_id>
    <nct_id>NCT03165253</nct_id>
  </id_info>
  <brief_title>The Effects of a Synbiotic Addition on Eradication Therapy of Helicobacter Pylori Infection in Children</brief_title>
  <official_title>The Effects of the Synbiotic &quot;Bifidobacterium Lactis B94 Plus Inulin&quot; Addition on Standard Triple Therapy of Helicobacter Pylori Eradication in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bulent Ecevit University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bulent Ecevit University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the effects of the synbiotic Bifidobacterium animalis
      ssp. lactis B94 plus inulin addition to the standard triple therapy on Helicobacter pylori
      infection eradication rates in children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aims to evaluate the effects of the synbiotic Bifidobacterium animalis ssp. lactis
      B94 plus inulin addition to the standard triple therapy on the eradication rates of
      Helicobacter pylori (H. pylori) infection in children. The subjects are children between 6 to
      16 years old who had biopsy proven H. pylori infection. The subjects will be randomly
      classified into two groups. The first group will receive the standard triple therapy
      consisting of amoxicillin oral tablet (50 mg/kg/day) + clarithromycin oral tablet (15
      mg/kg/day) + omeprazole oral capsule (1mg/kg/day). The second group will receive the standard
      triple therapy and Bifidobacterium animalis ssp. lactis B94 (5000000000 colony forming
      units/dose) plus inulin (900 mg) containing sachet for 14 days, concurrently. Eradication
      will be determined by 14-Carbon-urea breath test 4-6 weeks after therapy discontinuation. The
      eradication rates, the occurrence of side effects and the alterations of initial symptoms
      will be compared between the groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The eradication rates</measure>
    <time_frame>4-6 weeks after cessation of treatment</time_frame>
    <description>The eradication of H. pylori infection will be assessed by 14-carbon-urea breath test and the difference between eradication rates will be compared between the study groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The eradication therapy associated side effects</measure>
    <time_frame>14 days period during the treatment</time_frame>
    <description>Patients will be monitored at clinical visits and will be asked to recall for any side effects during the treatment protocol.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Synbiotic Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients will be treated with the standard triple therapy that consists of amoxicillin oral tablet 50 mg/kg/d and clarithromycin oral tablet 15 mg/kg/d twice daily for 14 days, and omeprazole 1 mg/kg/d once daily for a month, and the synbiotic Bifidobacterium animalis oral product (5000000000 colony forming units/dose) plus inulin (900 mg) given a single dose for 14 days, concurrently.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Therapy Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The patients in this group will be treated with standard triple therapy only. The standard triple therapy consists of amoxicillin oral tablet 50 mg/kg/d and clarithromycin oral tablet 15 mg/kg/d twice daily for 14 days, and omeprazole 1 mg/kg/d once daily for a month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bifidobacterium Animalis Oral Product</intervention_name>
    <description>The synbiotic group will receive this product.</description>
    <arm_group_label>Synbiotic Group</arm_group_label>
    <other_name>Bifidobacterium lactis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin Oral Tablet</intervention_name>
    <description>50mg/kg/day B.I.D.</description>
    <arm_group_label>Synbiotic Group</arm_group_label>
    <arm_group_label>Standard Therapy Group</arm_group_label>
    <other_name>Amoxicillin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin Oral Tablet</intervention_name>
    <description>15 mg/kg/day B.I.D.</description>
    <arm_group_label>Synbiotic Group</arm_group_label>
    <arm_group_label>Standard Therapy Group</arm_group_label>
    <other_name>Clarithromycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>1 mg/kg/day</description>
    <arm_group_label>Synbiotic Group</arm_group_label>
    <arm_group_label>Standard Therapy Group</arm_group_label>
    <other_name>Omeprazole Capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children who are investigated by a standard esophagogastroduodenoscopy (EGD) for
             gastrointestinal symptoms those suggesting of an organic disease such as chronic
             abdominal pain, unexplained nausea and/or vomiting, severe regurgitation,
             gastrointestinal bleeding, unexplained weight loss, or chronic diarrhea and who are
             found to be H. pylori positive in gastric biopsies are included in the study.

        Exclusion Criteria:

          -  Patients who were treated for H. pylori infection previously, or who used an
             antimicrobial agent, bismuth, a non-steroid anti-inflammatory drug, or any form of
             gastric acid suppressor during the eight weeks prior to EGD, or who had history of
             major gastrointestinal surgery, chronic renal or hepatic disease and who were known to
             have drug allergy were excluded from the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gonca H Ustundag, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate professor</affiliation>
  </overall_official>
  <reference>
    <citation>Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ; European Helicobacter Study Group. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012 May;61(5):646-64. doi: 10.1136/gutjnl-2012-302084.</citation>
    <PMID>22491499</PMID>
  </reference>
  <reference>
    <citation>Koletzko S, Jones NL, Goodman KJ, Gold B, Rowland M, Cadranel S, Chong S, Colletti RB, Casswall T, Elitsur Y, Guarner J, Kalach N, Madrazo A, Megraud F, Oderda G; H pylori Working Groups of ESPGHAN and NASPGHAN. Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr. 2011 Aug;53(2):230-43. doi: 10.1097/MPG.0b013e3182227e90.</citation>
    <PMID>21558964</PMID>
  </reference>
  <results_reference>
    <citation>Gotteland M, Brunser O, Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Aliment Pharmacol Ther. 2006 Apr 15;23(8):1077-86. Review.</citation>
    <PMID>16611267</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>May 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2017</study_first_posted>
  <last_update_submitted>May 23, 2017</last_update_submitted>
  <last_update_submitted_qc>May 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bulent Ecevit University</investigator_affiliation>
    <investigator_full_name>Gonca Handan Ustundag</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori infection</keyword>
  <keyword>Children</keyword>
  <keyword>Synbiotic</keyword>
  <keyword>Standard Triple Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

